Rezultati pretraživanja
  1. prije 14 sati

    Fight CRC webinar Dr. Axel Grothey with a recap of some of the research presented at the for Here's a link to a time stamp outline of the topics: REGONIVO, BEACON, CHECKMATE 142, Liquid Biopsies & COBRA trial, IPACS study

  2. prije 15 sati

    Danielle S. Bitterman, MD, on Pancreatic Cancer: Noninvasive Genomic Profiling From Plasma ctDNA

  3. prije 17 sati

    "A small study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose."

  4. Should the recommended colonoscopy screening age be lowered? Uri Ladabaum, MD of and David Weinberg, MD of debated on the matter during the and also discussed the debate during an interview with Targeted Oncology.

  5. prije 17 sati

    Scott Kopetz, MD, PhD, on Metastatic Colorectal Cancer: Quality of Life Results on Encorafenib, Cetuximab, and Binimetinib

  6. No sound is sweeter to my ears than personalized supportive cancer care. Precision cancer care delivery (a la stellar keynote at ) is just as critical as NGS in provider truly comprehensive cancer care. Can't wait!

  7. prije 20 sati

    Brian M. Wolpin, MD, on Performance of a Blood-Based Test for the Detection of Multiple @HaleCenter_DFCI

  8. prije 20 sati

    Atualização dos dados do BEACON trial na ASCO GI mantendo ganho de SG e com qualidade de vida! Doublet como standard no tratamento p/pts CCRm BRAFm V600E pós falha a 1a linha. Pena que custo ainda exorbitante + vale mais uma vez a discussão de valor na oncologia!

  9. 5. velj

    In the cohort of patients that received lenvatinib in the frontline setting, the ORR was 14.0% versus 4.0% in those that received therapy in the second- to fourth-line settings.

  10. 4. velj

    On , we recognize pharmacists who are advancing the treatment of cancer. Assistant Professor Ashley Glode, PharmD, recently presented a poster at the showing that less chemotherapy may have more benefit in rectal cancer.

  11. 4. velj

    Here we are ! Updates from are now ready! Videos released and downloadable slides available on our website. Please enjoy reading and watching!!

  12. 3. velj

    Dr. Lenz “The incredible complete response rates & overall response rates seen are never seen with chemotherapy, & it’s very well tolerated, so if I have a choice, I would start with nivolumab-ipilimumab in 1st-line -H...” from ASCO

  13. 1. velj

    This combination resulted in an overall response rate of 81% in patients with RAS/BRAF-wildtype metastatic colorectal cancer.

  14. 31. sij
    Odgovor korisniku/ci

    I was told by an expert at ASCO that lung mets also respond better to immunotherapy than liver mets.

  15. 31. sij
  16. 31. sij

    "Meetings like serve as an important reminder of the brilliant and compassionate people around the world who are working every day to improve outcomes for patients facing GI cancers, like ."

  17. 31. sij
  18. 31. sij
  19. 30. sij

    "Hit the wall" last night... with some patient advocacy burnout. LOVED going to ASCO ... but need to get the damn dishes washed! My motto today: try to do the least I can do. Feel better already!

  20. 30. sij

    There may be a gut microbe connection to the increased incidence of CRC in younger patients.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.